Progentec Diagnostics Secures Series B Funding to Advance Lupus Diagnostic Tools and Acquires LupusCorner to Build Comprehensive Patient Management Platform

Recently, VCBeat (WeChat: vcbeat) learned from foreign media that Progentec Diagnostics (“Progentec”), a leader in diagnostic technology innovation, announced the completion of its Series B financing round, co-led by i2E and OCA Ventures. The round also received support from NMC Lifesciences, a global leading healthcare provider. The new funding will help accelerate the commercialization of Progentec’s lupus testing tools. Specific financing amounts and details have not been disclosed.

On the same day, Progentec also announced the acquisition of LupusCorner, a health management platform serving patients with systemic lupus erythematosus (SLE) and lupus nephritis. Progentec aims to develop a best-in-class lupus patient management platform by integrating LupusCorner’s technology platform and data insights.

Image source: Progentec Diagnostics official website

Lupus is an autoimmune disease that primarily affects women aged 15 to 44. This condition causes the patient’s immune system to recognize and attack their own healthy tissues. Lupus can trigger localized inflammation in various parts of the body, including the joints, skin, kidneys, blood cells, brain, and heart. The disease is often difficult to diagnose because its symptoms and signs are typically very similar to those of other conditions. According to estimates by the Lupus Foundation of America, there are currently up to 1.5 million people in the United States alone living with lupus (systemic lupus erythematosus, or SLE).

Progentec’s technologies include highly accurate biomarker-based assays for disease diagnosis prior to symptom onset, as well as monitoring and predicting disease activity levels in lupus. The core technology underlying its platform under development is provided by the Oklahoma Medical Research Foundation (OMRF) in the United States.

LupusCorner was founded in 2016 with the aim of improving the experience of lupus patients through user-friendly and powerful technology. Currently, nearly 45,000 lupus patients engage with the LupusCorner platform each month.

Mohan Purushothaman, CEO of Progentec, stated, “The addition of LupusCorner and its users further advances our vision of creating a comprehensive disease management platform, ensuring that the patient voice becomes an integral component of our ecosystem. We look forward to enhancing the platform to address the unmet market needs for lupus diagnosis and management tools.”

Progentec, founded in 2015 and headquartered in Oklahoma, USA, is a leader in the field of diagnostic technology innovation, dedicated to exploring the most advanced diagnostic interventions for commercialized healthcare. The company is currently actively seeking collaborations with research institutions and individuals worldwide to introduce cutting-edge technologies into the diagnostics sector. Previously, Progentec completed its seed funding round, raising a total of $1.3 million. Details of this latest financing round have not been disclosed.

LupusCorner, founded in 2016 and headquartered in Washington, D.C., United States, is a patient health management platform primarily serving patients with systemic lupus erythematosus (SLE) and lupus nephritis. Through its mobile software platform that supports patient tracking, LupusCorner generates patient data, provides healthcare information, and builds a patient community.